{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:27:07Z","timestamp":1760747227888,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01231-x","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:59:32Z","timestamp":1756637972000},"page":"2947-2958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystadrops\u00ae Eye Drops for the Management of Ocular Cystinosis in Patients Aged 6 Months to\u2009<\u20092 Years"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-0572","authenticated-orcid":false,"given":"Susmito","family":"Biswas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-1845","authenticated-orcid":false,"given":"Ingele","family":"Casteels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3563-5482","authenticated-orcid":false,"given":"Dominique","family":"Bremond-Gignac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4838-9417","authenticated-orcid":false,"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-5542","authenticated-orcid":false,"given":"Giancarlo","family":"Iarossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"1231_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40123-018-0146-6","volume":"7","author":"S Biswas","year":"2018","unstructured":"Biswas S, Gaviria M, Malheiro L, Marques JP, Giordano V, Liang H. Latest clinical approaches in the ocular management of cystinosis: a review of current practice and opinion from the Ophthalmology Cystinosis Forum. Ophthalmol Ther. 2018;7:307\u201322.","journal-title":"Ophthalmol Ther"},{"key":"1231_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40123-017-0089-3","volume":"6","author":"AM Pinxten","year":"2017","unstructured":"Pinxten AM, Hua MT, Simpson J, Hohenfellner K, Levtchenko E, Casteels I. Clinical practice: a proposed standardized ophthalmological assessment for patients with cystinosis. Ophthalmol Ther. 2017;6:93\u2013104.","journal-title":"Ophthalmol Ther"},{"key":"1231_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-016-0426-y","volume":"11","author":"MA Elmonem","year":"2016","unstructured":"Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko E. Cystinosis: a review. Orphanet J Rare Dis. 2016;11:47.","journal-title":"Orphanet J Rare Dis"},{"key":"1231_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.kint.2021.06.019","volume":"100","author":"F Emma","year":"2021","unstructured":"Emma F, Hoff WV, Hohenfellner K, et al. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int. 2021;100:1112\u201323.","journal-title":"Kidney Int"},{"key":"1231_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s43054-024-00317-8","volume":"72","author":"R Helmy","year":"2024","unstructured":"Helmy R, Mahmoud RS, Elmonem MA, Emadeldin S, Soliman NAS. Role of biomarkers of inflammation and MRI technique for the early detection of cystinosis-associated myopathy. Egypt Pediatr Assoc Gaz. 2024;72:72.","journal-title":"Egypt Pediatr Assoc Gaz"},{"issue":"Suppl 1","key":"1231_CR6","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1007\/s00431-003-1349-x","volume":"162","author":"WA Gahl","year":"2003","unstructured":"Gahl WA. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr. 2003;162(Suppl 1):S38-41.","journal-title":"Eur J Pediatr"},{"key":"1231_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jimd.12562","volume":"46","author":"K Veys","year":"2023","unstructured":"Veys K, Zadora W, Hohenfellner K, et al. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: a multicenter sibling cohort study. J Inherit Metab Dis. 2023;46:43\u201354.","journal-title":"J Inherit Metab Dis"},{"key":"1231_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/cells11020190","volume":"11","author":"MA Elmonem","year":"2022","unstructured":"Elmonem MA, Veys KR, Prencipe G. Nephropathic cystinosis: pathogenic roles of inflammation and potential for new therapies. Cells. 2022;11:190.","journal-title":"Cells"},{"key":"1231_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.nefro.2015.05.019","volume":"35","author":"G Ariceta","year":"2015","unstructured":"Ariceta G, Camacho JA, Fern\u00e1ndez-Obispo M, et al. Cystinosis in adult and adolescent patients: recommendations for the comprehensive care of cystinosis. Nefrologia. 2015;35:304\u201321.","journal-title":"Nefrologia"},{"key":"1231_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ymgme.2022.06.010","volume":"136","author":"C Nie\u00dfl","year":"2022","unstructured":"Nie\u00dfl C, Boulesteix AL, Oh J, et al. Relationship between age at initiation of cysteamine treatment; adherence with therapy; and glomerular kidney function in infantile nephropathic cystinosis. Mol Genet Metab. 2022;136:268\u201373.","journal-title":"Mol Genet Metab"},{"key":"1231_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ymgme.2022.06.009","volume":"136","author":"K Hohenfellner","year":"2022","unstructured":"Hohenfellner K, Nie\u00dfl C, Haffner D, et al. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis. Mol Genet Metab. 2022;136:282\u20138.","journal-title":"Mol Genet Metab"},{"key":"1231_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1136\/bjo-2023-325093","volume":"109","author":"H Liang","year":"2025","unstructured":"Liang H, Baudouin C, Giordano V. Evaluation of a new classification system for measuring the progression of ocular cystinosis: an analysis of 64 patients. Br J Ophthalmol. 2025;109:442\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"S","key":"1231_CR13","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jpeds.2016.12.055","volume":"183","author":"R Bishop","year":"2017","unstructured":"Bishop R. Ocular complications of infantile nephropathic cystinosis. J Pediatr. 2017;183(S):S19\u201321.","journal-title":"J Pediatr"},{"key":"1231_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.survophthal.2006.10.006","volume":"52","author":"E Tsilou","year":"2007","unstructured":"Tsilou E, Zhou M, Gahl W, Sieving PC, Chan CC. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007;52:97\u2013105.","journal-title":"Surv Ophthalmol"},{"key":"1231_CR15","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1167\/iovs.15-16499","volume":"56","author":"H Liang","year":"2015","unstructured":"Liang H, Baudouin C, Tahiri Joutei Hassani R, Brignole-Baudouin F, Labb\u00e9 A. Photophobia and corneal crystal density in nephropathic cystinosis: an in vivo confocal microscopy and anterior-segment optical coherence tomography study. Invest Ophthalmol Vis Sci. 2015;56:3218\u201325.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1231_CR16","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1111\/aos.14569","volume":"99","author":"L Keidel","year":"2021","unstructured":"Keidel L, Elhardt C, Hohenfellner K, et al. Establishing an objective biomarker for corneal cystinosis using a threshold-based spectral domain optical coherence tomography imaging algorithm. Acta Ophthalmol. 2021;99:e189\u201395.","journal-title":"Acta Ophthalmol"},{"key":"1231_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/ICO.0000000000003161","volume":"42","author":"S Biswas","year":"2023","unstructured":"Biswas S, Alzahrani K, Radhakrishnan H. Corneal densitometry to assess the corneal cystine deposits in patients with cystinosis. Cornea. 2023;42:313\u20139.","journal-title":"Cornea"},{"key":"1231_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/mgme.2000.3062","volume":"71","author":"WA Gahl","year":"2000","unstructured":"Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab. 2000;71:100\u201320.","journal-title":"Mol Genet Metab"},{"key":"1231_CR19","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1167\/iovs.16-21080","volume":"58","author":"H Liang","year":"2017","unstructured":"Liang H, Labb\u00e9 A, Le Mouha\u00ebr J, Plisson C, Baudouin C. A new viscous cysteamine eye drops treatment for ophthalmic cystinosis: an open-label randomized comparative phase III pivotal study. Invest Ophthalmol Vis Sci. 2017;58:2275\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1231_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/bjophthalmol-2020-316450","volume":"105","author":"H Liang","year":"2021","unstructured":"Liang H, Labb\u00e9 A, Baudouin C, Plisson C, Giordano V. Long-term follow-up of cystinosis patients treated with 0.55% cysteamine hydrochloride. Br J Ophthalmol. 2021;105:608\u201313.","journal-title":"Br J Ophthalmol"},{"key":"1231_CR21","unstructured":"Cystadrops. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cystadrops. Accessed 20 June 2025."},{"key":"1231_CR22","unstructured":"Cystadrops - opinion on variation to marketing authorisation. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/cystadrops. Accessed 20 June 2025."},{"key":"1231_CR23","unstructured":"Cystadrops\u2014summary of product characteristics. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250606166420\/anx_166420_en.pdf. Accessed 23 June 2025."},{"key":"1231_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/opo.12310","volume":"36","author":"DB Elliott","year":"2016","unstructured":"Elliott DB. The good (logMAR); the bad (Snellen) and the ugly (BCVA; number of letters read) of visual acuity measurement. Ophthalmic Physiol Opt. 2016;36:355\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1231_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/jpr.02486","volume":"2","author":"\u00d6N \u015eahin","year":"2015","unstructured":"\u015eahin \u00d6N, G\u00fclen F. Approach to common cold in children. J Pediatr Res. 2015;2:1\u20136.","journal-title":"J Pediatr Res"},{"key":"1231_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1566524015666150731095426","volume":"15","author":"CE Egwuagu","year":"2015","unstructured":"Egwuagu CE, Sun L, Kim SH, Dambuza IM. Ocular inflammatory diseases: molecular pathogenesis and immunotherapy. Curr Mol Med. 2015;15:517\u201328.","journal-title":"Curr Mol Med"},{"key":"1231_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41467-017-02536-7","volume":"9","author":"BP Festa","year":"2018","unstructured":"Festa BP, Chen Z, Berquez M, et al. Impaired autophagy bridges lysosomal storage disease and epithelial dysfunction in the kidney. Nat Commun. 2018;9:161.","journal-title":"Nat Commun"},{"key":"1231_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01170-7","author":"E Matthys","year":"2025","unstructured":"Matthys E, Delbeke H, Van Keer K, Casteels I. The use of a viscous cysteamine eyedrop in a Belgian cohort: early 3-year results. Ophthalmol Ther. 2025. https:\/\/doi.org\/10.1007\/s40123-025-01170-7.","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"1231_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3921\/joptom.2009.19","volume":"2009","author":"S Leat","year":"2009","unstructured":"Leat S, Yadav N, Irving E. Development of visual acuity and contrast sensitivity in children. J Optom. 2009;2009(2):19\u201326.","journal-title":"J Optom"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01231-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01231-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:43Z","timestamp":1760715763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01231-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1231"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01231-x","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"type":"print","value":"2193-8245"},{"type":"electronic","value":"2193-6528"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Susmito Biswas, Julien Hogan and Giancarlo Iarossi have received speaker honoraria from Recordati Rare Diseases. Dominique Bremond-Gignac and Ingele Casteels have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki 1964 and all subsequent amendments, and approved by the appropriate ethics Committees of Belgium, Italy, France and the UK. The ethics boards are: Ethische Commissie Onderzoek UZ\/KU Leuven, Campus Gasthuisberg E330, Herestraat 49, 3000 Leuven, Belgium; Bambino Ges\u00f9 Hospital, Rome, Italy; Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9, France; Health Research Authority (HRA) and Health and Care Research Wales (HCRW). Protocol number CYT-C2-001, date of approval 18\/09\/19. Written informed consent was obtained from each patient\u2019s parents or legally acceptable representatives prior to any study procedures being performed. As patients were under 2 years of age, they were not required to provide assent for their participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}